NHS England's Advice to Clinicians about Offering Risdiplam EAMS

12 February 2021

The NHS England Nusinersen Clinical Panel, which is also established to offer advice more generally on the treatment and care of patients with SMA, was asked to develop a framework of advice to assist clinicians to understand and interpret the risdiplam EAMS.

NHS England describe this information as a: "framework of advice for clinicians to assist in interpreting the EAMS scientific opinion and [it] is not a directive from NHS England. The Clinical Panel understands that each patient case has unique factors and the treating physician must acknowledge that the patient fits the EAMS indication of not suitable for authorised treatments."

NHS England Risdiplam EAMS Framework

It's best to be read in context alongside the other risdiplam EAMS Q&As that have already been published:

September 2020 - FAQs from Patient Groups to Roche

January 2021 - FAQs from Families & Adults to Clincians

Though we welcome this advice from NHS England and the clinical panel about who should have access to the risdiplam EAMS, we are very aware that many, particularly adults, are still unable to access nusinersen or risdiplam at their treatment centre. We continue to work hard to change this as a matter of urgency.